Disease-A-Month
Volume 53, Issue 4 , Pages 214-222 , April 2007

Current Pharmacotherapeutic Treatment Options in Parkinson’s Disease

References 

  1. Jankovic J. Progression of Parkinson’s disease: are we making progress in charting the course?. Arch Neurol. 2005;62:351–352
  2. Antonin A, DSeNotaris R. And SPECT functional imaging in Parkinson’s disease. Sleep Med. 2004;5:201–206
  3. Chadhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–245
  4. Kumar A, Calne SM, Schulzer M, et al. Clustering of Parkinson’s disease: shared cause or coincidence?. Arch Neurol. 2004;61:1057–1060
  5. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational and other etiologic factors. I. Parkinson’s disease: a case control study in Germany. Neurology. 1996;46:1275–1284
  6. Parkinson J. An Essay on the Shaking Palsy. London, England: Sherwood, Nealy and Jones; 1817;
  7. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson’s disease should begin with a dopamine agonist. Mov Disord. 1999;14:725–730
  8. Williams GR, Kurland LT, Goldberg ID. Morbidity and mortality with parkinsonism. J Neurosurg. 1966;24:138–143
  9. Cotzias GC, Van WM, Schiffer LM. Aromatic amino acids and the modification of parkinsonism. N Engl J Med. 1967;276:374–379
  10. Routtinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in Parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996;60:36–40
  11. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-placebo-controlled trial. Neurology. 1997;48(1):81–87
  12. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the “wearing off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997;49:1066–1071
  13. Colosimo C. The rise and fall of tolcapone. J Neurol. 1999;246(10):880–882
  14. Olanow WC. Tolcapone and hepatotoxic effects. Arch Neurol. 2000;57(2):263–267
  15. Olanow CW, Calne D. Does selegeline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms?. Neurology. 1992;42(suppl 4):13
  16. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176
  17. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients not requiring levodopa. Ann Neurol. 1996;39:29–36
  18. Parkinson Study Group. Impact of deprenyl on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39:37–45
  19. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1998;321:1364–1371
  20. Olanow CW, Mytilineou C, Tatton W. Current status of selegeline as a neuroprotective agent in Parkinson’s disease. Mov Disord. 1998;13(suppl 1):55–58
  21. Tatton WG, Wadia JS, Ju WY, et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl. 1996;48:45–49
  22. Stern MB, Marek KL, Freidman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord. 2004;19:916–923
  23. Rascol O, Brooks D, Melamed E, et al. Rasagaline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagaline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2003;365:947–954
  24. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord. 1998;13(5):798–802
  25. Verhagen Metman L, Del Dotto P, Blanchet PJ, et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids. 1998;14(1-3):75–82
  26. Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2, and D-3 receptors. Eur J Pharmacol. 1999;366:293–300
  27. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol. 1995;18(4):338–347
  28. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the early treatment of Parkinson’s disease. Neurology. 1997;49:393–399
  29. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson’s disease. Curr Opin Neurol. 2004;17(4):393–398
  30. Lieberman A. Dopamine agonists used as monotherapy in de novo Parkinson’s disease patients: comparisons with selegeline. Neurology. 1992;42(suppl 4):37–40
  31. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double blind, placebo controlled, parallel-group study. Neurology. 1997;49:162–168

PII: S0011-5029(07)00040-5

doi: 10.1016/j.disamonth.2007.05.002

Disease-A-Month
Volume 53, Issue 4 , Pages 214-222 , April 2007

Article Tools